RxDoctor Payments Data

Roxy Sheffield

Medical · Waycross, GANPI 1831456409

Payments from drug & device makers

$7,922in general payments, 2019–2025

Across 487 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$959
  • Lilly USA, LLC$555
  • Pfizer$420
  • Boston Scientific$369
  • Amgen$276
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,85699%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,922 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$37,372
Medicare patients
102
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide65$98,949
OzempicSemaglutide56$90,596
VraylarCariprazine Hcl17$26,320
TrulicityDulaglutide18$23,748
Tresiba Flextouch U-200Insulin Degludec11$20,243
EliquisApixaban20$19,965
JardianceEmpagliflozin15$17,531
LinzessLinaclotide12$14,668
QuliptaAtogepant12$13,256
Emgality PenGalcanezumab-Gnlm11$7,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,415
SymbicortBudesonide/Formoterol Fumarate18$4,010
ProgesteroneProgesterone, Micronized70$2,905
Testosterone Cypionate63$2,861
Lidocaine12$2,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$555$122,69783 claims
Novo NordiskOzempic$959$90,59656 claims
AbbVieVraylar, Linzess, Qulipta, Synthroid, Armour Thyroid$2,303$57,24479 claims
PfizerEliquis$420$19,96520 claims
Boehringer IngelheimJardiance$97$17,53115 claims
AstraZenecaBreztri Aerosphere, Symbicort$65$11,42530 claims
Acella Pharmaceuticals, LLCNp Thyroid$19$1,35023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.

Other medical in Waycross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →